Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting

EBioMedicine(2025)10.1016/j.ebiom.2025.105628Source: DataRank Database

Safety, reactogenicity, and immunogenicity of MTBVAC in infants: a phase 2a randomised, double-blind, dose-defining trial in a TB endemic setting is a research paper published in EBioMedicine (2025). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 8.98)OA: goldTopics (47)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (63)

Virginie Rozot ORCID,Claire Imbratta,Hennie Geldenhuys ORCID,Simon C. Mendelsohn ORCID,Angelique Kany Kany Luabeya ORCID

Live enrichment

PubMed:40101388 PMC:PMC12121429 OpenAlex:https://openalex.org/W4408531667

University of Capetown

Grant: MTBVAC202

European & Developing Countries Clinical Trials Partnership (EDCTP)

Grant: RIA2016V-1637

European & Developing Countries Clinical Trials Partnership (EDCTP)

Congressionally Directed Medical Research Programs

National Institutes of Health

FWCI

8.98

Citation Percentile

1.0%

Citation Trend

2025

2026

goldLicense: cc-by-nc

journalhttps://doi.org/10.1016/j.ebiom.2025.105628

publisherhttps://doi.org/10.1016/j.ebiom.2025.105628

publisherhttps://api.elsevier.com/content/article/PII:S2352396425000726?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2352396425000726?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40101388

Fields of Study

Tuberculosis Research and EpidemiologyImmunodeficiency and Autoimmune DisordersImmune responses and vaccinationsFemaleHumansMaleBCG VaccineDouble-Blind MethodImmunogenicity, VaccineMycobacterium tuberculosisSouth AfricaTuberculosisTuberculosis VaccinesVaccinationVaccines, AttenuatedInfant, Newborn

MeSH Terms

Immunogenicity, VaccineBCG VaccineDouble-Blind MethodFemaleHumansInfantInfant, NewbornMaleMycobacterium tuberculosisSouth AfricaTuberculosisVaccinationVaccines, AttenuatedTuberculosis Vaccines

Keywords

ReactogenicityImmunogenicityMedicineDouble blindPediatricsPhase (matter)ImmunologyAlternative medicineAntibodyPathologyPlaceboPhysicsMycobacterium tuberculosisTuberculosisInfantVaccineBCG

Sustainable Development Goals

SDG 0: Good health and well-being